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Abstract: Background and Aim: Glypican-3 (GPC3) is a novel molecular target for hepatocellular carcinoma (HCC). This 
study investigated the potential of an L5 peptide-guided pretargeting approach to identify GPC3-expressing HCC cells 
using ultra-small super-paramagnetic iron oxide (USPIO) as the MRI probe. 
Methods: Immunofluorescence with carboxyfluorescein (FAM)-labeled L5 peptide was performed in HepG2 and HL-7702 
cells. Polyethylene glycol-modified ultrasmall superparamagnetic iron oxide (PEG-USPIO) and its conjugates with 
streptavidin (SA-PEG-USPIO) were synthesized, and hydrodynamic diameters, zeta potential, T2 relaxivity, and 
cytotoxicity were measured. MR T2-weighted imaging of HepG2 was performed to observe signal changes in the 
pretargeting group, which was first incubated with biotinylated L5 peptide and then with SA-PEG-USPIO. Prussian blue 
staining of cells was used to assess iron deposition. 
Results: Immunofluorescence assays showed high specificity of L5 peptide for GPC3. SA-PEG-USPIO nanoparticles 
had ≈36 nm hydrodynamic diameter, low toxicity, negative charge and high T2 relaxivity. MR imaging revealed that a 
significant negative enhancement was only observed in HepG2 cells from the pretargeting group, which also showed 
significant iron deposition with Prussian blue staining. 
Conclusion: MR imaging with USPIO as the probe has potential to identify GPC3-expressing HCC through L5 peptide-
guided pretargeting approach. 
Keywords: Hepatocellular carcinoma, magnetic resonance imaging, peptide ligand, iron oxide. 
INTRODUCTION 
Hepatocellular carcinoma (HCC) is one of the most 
common human malignancies that affect diverse 
populations worldwide [1]. Early diagnosis plays a vital 
role in the management and treatment of patients with 
HCC. As mainstay imaging modalities, conventional 
contrast-enhanced computed tomography (CT) and 
magnetic resonance (MR) imaging suffer from low 
sensitivity and specificity for small HCC, especially 
lesions smaller than a centimeter [2], leading to a 
possible delay in diagnosis. A variety of novel CT and 
MRI technologies have been explored, such as 
perfusion CT or MRI, diffusion-weighted MR imaging, 
and MR imaging with superparamagnetic iron oxide 
(SPIO), ultrasmall superparamagnetic iron oxide 
(USPIO), or hepatobiliary agents. While these methods 
offer an increase in our ability to detect HCC, there is 
still much room for improvement [3-6]. Two major 
factors that need to be addressed are the formidable 
reticulo-endothelial system of the liver that eliminates 
extraneous contrast agents, and tumor heterogeneity in 
terms of radiological features [2, 7]. 
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Molecular MR imaging using magnetic 
nanoparticles (NPs) to specifically target tumor cells 
has been well documented as a good method to 
address issues with HCC diagnosis [8-10]. Glypican-3 
(GPC3) may be the most promising among the specific 
molecular targets for HCC; it is highly expressed on 
most HCC cells while absent in normal liver 
parenchyma or benign liver lesions [11-12], and is 
more specific and sensitive than current biomarkers for 
small HCC, such as alpha-fetoprotein [12-15]. Sham et 
al. successfully identified HCC foci using 89Zr coupled 
with an anti-GPC3 monoclonal antibody (aGPC3) as a 
PET probe [16], and MRI can be used to detect HCC of 
very small size with USPIO-aGPC3 as a molecular 
probe [12]. Monoclonal antibodies (moAb) are widely 
used as ligands in molecular imaging for their 
extraordinary targeting specificity and affinity for tumor 
biomarkers [17]. However, several inherent limitations 
of moAb, such as immunogenicity and high cost, 
severely hinder clinical translation of moAb-based 
approaches [18]. As an alternative to moAb, tumor 
homing peptides can be chosen as effective vectors to 
guide imaging probes to tumor cells [19-23]. Moreover, 
peptide ligands offer several advantages over moAbs, 
such as fast blood clearance and excellent tissue 
penetration, which may produce a higher tumor-to-
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background ratio [24]. The L5 peptide consists of 14 
amino acids (Arg-Leu-Asn-Val-Gly-Gly-Thr-Tyr-Phe-
Leu-Thr-Thr-Arg-Gln) and targets GPC3-expressing 
HCC [23]. To the best of our knowledge, there is no 
published report on molecular MR imaging of HCC 
using L5 peptide targeting. 
In this study, L5 peptide was utilized to bind GPC3 
in HCC cells, and then biotinylation was employed to 
bridge superparamagnetic NPs with the L5 peptide 
through a two-step pretargeting protocol (Figure 1). In 
vitro MR imaging and histologic examination were 
performed to evaluate the specificity and feasibility of 
the L5 peptide-based approach to identify GPC3-
expressing HCC cells. 
MATERIALS AND METHODS 
Materials 
L5 peptide (Arg-Leu-Asn-Val-Gly-Gly-Thr-Tyr-Phe-
Leu-Thr-Thr-Arg-Gln) was purchased from Bambio Co, 
Ltd (Xiamen, China). FAM, 4′,6-diamidino-2-phenyli-
ndole (DAPI), 0.1M 2-morpholino-ethanesulfonic acid 
(MES) buffer solution, 1-ethyl-3-[3-dimethylaminopro-
pyl] carbodiimide hydrochloride (EDC), sulfo-NHS, 
H2N-PEG-COOH, MTT, Sulfo-NHS-LC-Biotin, and 
streptavidin (SA) were purchased from Sigma-Aldrich 
(St Louis, MO, USA). Dimethyl sulfoxide (DMSO), 4% 
paraformaldehyde, 2-mercaptoethanol, ethanolamine, 
and agarose were purchased from Aladdin-reagent 
(Shanghai, China). USPIO with carboxylate was 
purchased from Oneder Hightech Co. Ltd (Beijing 
China). All other chemicals were of analytical grade. 
Cell Culture 
HepG2 and HL-7702 cell lines were gifts from the 
Research Center of Clinical Medicine in Nanfang 
Hospital (Guangdong province, China). Both cell lines 
were routinely grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% (v/v) fetal bovine 
serum and 1% streptomycin-penicillin in a humidified 
incubator at 37 ℃ with 5% CO2. 
Synthesis of L5-FAM 
L5 peptide (1.0 mg/ml, 1.0 ml) was combined with 
15 µg EDC and 20 µg of sulfo-NHS, and stirred for 20 
minutes to activate the carboxyl group of the peptide. A 
desalting column was used to remove excessive EDC 
and sulfo-NHS, followed by the addition of 0.2 ml of 
FAM (1.0 mg/ml). The mixture was stirred at 4 ℃ in the 
dark for 12 hours. Excessive FAM was removed using 
the desalting column. 
In Vitro Fluorescence Imaging 
Fluorescence imaging was performed to verify the 
selective affinity of L5 peptide to GPC3-expressing 
 
Figure 1: Schematic of the two-step pretargeting method using L5 peptide. 
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HCC cells. HepG2 and HL-7702 cells were cultured on 
six-well chamber slides (5×105 per slide) and grown for 
24 hrs at 37 ℃. Cells were washed with PBS three 
times, and fixed in 4% paraformaldehyde/PBS solution 
for 30 min. The fixative was then removed, and cells 
were washed again with PBS three times. The slides 
were incubated with 0.1mg/ml of L5-FAM or FAM in 
PBS/1% BSA, and then stained with DAPI for nuclear 
counterstaining. A blocking assay was conducted to 
evaluate L5 peptide specificity for GPC3, where the 
slides were incubated with 1mg/ml L5 peptide before 
adding 0.1mg/ml L5-FAM. Stained cells were observed 
with a fluorescence microscope (Eclipse TS100, 
Nikon). 
Preparation of USPIO-PEG and SA-USPIO-PEG 
A total of 10.0 mg of USPIO-COOH was dissolved 
in 10 mL MES buffer (pH 5.5). EDC (0.6 mg) and sulfo-
NHS (0.4 mg) were added to the mixture to activate the 
carboxyl. After 20 minutes, a desalting column was 
used to remove excessive EDC and sulfo-NHS. H2N-
PEG-COOH (0.6 g) was added to the solution while 
stirring, and excessive PEG was removed. Then the 
PEG-USPIOs were concentrated by permanent 
magnet, and dissolved in MES buffer. 
EDC (2.0 mg) and sulfo-NHS (5.5 mg) were added 
to PEG-USPIO in 0.1M MES buffer solution, and the 
reaction was maintained for 15 minutes at room 
temperature (RT) and then quenched with 2-
mercaptoethanol. The solvent was removed by 
centrifugation at RT for 20 minutes at 2500 g (Millipore 
Amicon Ultra), the resultant NPs re-suspended in PBS 
buffer solution and mixed with SA (3.0 mg SA) for 2 
hours while stirring at RT before the reaction was 
stopped by adding ethanolamine. Finally, the solution 
was ultrafiltered by centrifugation and the concentration 
was adjusted to 1.0 mg Fe/ml in PBS (pH 7.4). 
NP Characterization  
The surface charge and mean size distribution of 
PEG-USPIO and SA-USPIO-PEG in PBS were 
determined using Malven Zeta 3000HS (Malvern 
Instruments, Malvern, UK) operating at 633.0nm and 
25.00 ± 0.05 ℃. 
Magnetic Property Measurements 
The T2 relaxivity of PEG-USPIO and SA-USPIO-
PEG was evaluated at 3.0T MR system (Signa Excite; 
General Electric, USA) using T2 mapping sequence 
(TR=2000 ms, TE = 20, 40, 60, 80 ms, FOV=75×75 
mm). Each NP was prepared in Fe concentrations of 
0.04, 0.06, 0.08, 0.10, 0.12, 0.14, 0.16, 0.20, 0.40, and 
0.60 mM. Images of the various solutions were 
analyzed by defining regions of interest (ROI) in each 
test tube. Relaxivity (R2) value was calculated through 
the curve-fitting of T2 (s–1) vs. the Fe concentration 
(µM). 
Cytotoxicity Assay 
In vitro cytotoxicity of the NPs (PEG-USPIO and 
SA-USPIO-PEG) was evaluated using the MTT assay 
in HL-7702 cells. In short, HL-7702 cells were seeded 
in 96-well plates at 6×103 cells/well for 24 hours, and 
then incubated with PEG-USPIO or SA-USPIO-PEG at 
different concentrations (0.4, 0.8, 1.2, 1.6, 2.0 and 2.4 
mM Fe) for 24 hours. Then, 20 µL of MTT (5.0 mg/mL) 
was added to each well and incubated for 4 hours, 
followed by the addition of 150 µL DMSO. The OD490 
value of each well was measured using a BIOTEK 
ELX800 microplate reader. The control group only 
contained cells and culture medium. 
Biotinylation of L5 
L5 peptides were biotinylated with Sulfo-NHS-LC-
Biotin following the manufacturer’s protocol. After 
purification with an Amicon Ultra-15 Centrifugal Filter 
Unit with a 1 kDa membrane from EMD Millipore 
(Billerica, MA, USA), the final biotin-peptide ratio was 
approximately 4, as determined by the HABA method. 
In Vitro MRI 
HepG2 and HL-7702 cells were seeded on 100 mm-
diameter cell culture dishes and grown overnight. For 
the pretargeting group, 0.2 mg/ml of L5-BT was added 
to identify and bind to GPC3 molecules on tumor cells 
for 1 hour. Cells were then washed three times with 
PBS before the incubation with SA-USPIO-PEG (Fe 
concentration of 1.8 mM) for 2 hours. For the non-
pretargeting group, cells were incubated with SA-
USPIO-PEG at the Fe concentration of 1.8 mM for 2 
hours. In the control group, cells were left untreated. All 
groups were detached using ethylene diamine tetra-
acetic acid (EDTA) 1:5000 (Invitrogen), centrifuged, 
resuspended in 1% agarose at a concentration of 
0.5×107 cells/ml, and then transferred into 1.5 ml 
centrifuge tubes. Six replicates for each group were 
performed. T2-weighted images were performed with 
SE sequence (TR=2500 ms, TE=96 ms, NEX=4, 
FOV=75×75 mm, thickness=2 mm, interval=2 mm). 
The T2WI signal intensity was normalized to that of 1% 
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agarose. T2 color maps of HepG2 and HL-7702 cells in 
3 different groups were obtained. 
Prussian Blue Staining 
According to standard clinical pathology protocols, 
both HepG2 and HL-7702 cells from the three groups 
(pretargeting, non-pretargeting and control) were 
stained with Prussian blue after MR imaging. 
Statistical Analysis 
All data are expressed as mean ± standard 
deviation. One-way analysis of variance and SNK were 
used to evaluate the differences of T2WI signal 
intensity among three groups. All tests were performed 
using SPSS version 13.0 (IBM Corporation, Armonk, 
NY, USA). Results were considered statistically 
significant when P<0.05. 
RESULTS 
In Vitro Fluorescence Imaging 
Cellular labeling with carboxyfluorescein (FAM) was 
visualized through fluorescence imaging. In the L5-
FAM group, extensive cell membrane labeling occurred 
in HepG2 (human hepatocellular carcinoma cells 
expressing GPC3) compared with HL-7702 (human 
normal hepatocytes not expressing GPC3) cells. In the 
FAM group, neither HepG2 cells nor HL-7702 cells 
were labeled. In the blocking group, an excess of free 
L5 peptide precluded the binding of FAM-labeled L5 
peptide to GPC3, resulting in a decreased fluorescent 
signal in HepG2 cells (Figure 2). 
Characterization of PEG-USPIO and SA-USPIO-PEG 
PEG-USPIO and SA-USPIO-PEG had an average 
hydrodynamic diameter of 22.73 nm and 35.97 nm, a 
polydispersity index of 0.207 and 0.169, and a zeta 
potential of 4.22 mV and -7.91 mV, respectively (Figure 
3). 
Magnetic Property Measurements 
The pseudocolored images of T2 values illustrated 
that the color of the tubes deepened with an increase in 
Fe concentration (Figure 4). R2 values were 
0.1394×103 mM-1s-1 and 0.1039×103 mM-1s-1 for PEG-
USPIO and SA-USPIO-PEG, respectively (Figure 5). 
Cytotoxicity Assay 
To evaluate the cytotoxicity of nanoparticles, HL-
7702 cells were incubated with PEG-USPIO and SA-
USPIO-PEG for 24 hours and then assessed cell 
viability via methyl thiazdyl tetrazolium (MTT) assay. As 
shown in Figure 6, cell viability did not significantly 
change with increasing iron concentrations, and still 
remained above 80% at the maximal Fe concentration. 
These results demonstrated that both NPs display low 
toxicity and may be biocompatible at the given Fe 
concentration range (0.4-2.4 mM). 
In Vitro MRI 
In vitro MR imaging was performed to test the 
feasibility of identifying GPC3-expressing HCC cells 
through the L5 peptide-mediated pretargeting 
 
Figure 2: L5 peptide binding assays for (A) HepG2 cells and (B) HL-7702 cells. Cells were incubated with either L5-FAM or 
FAM alone. Excess L5 protein was given to HepG2 cells with L5-FAM to exemplify competitive binding (“Blocking”) and strong 
affinity of these compounds to GPC3. 
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Figure 3: Dynamic light scattering data for (A) PEG-USPIO and (B) SA-USPIO-PEG. 
 
 
Figure 4: The T2 color maps of (A) PEG-USPIO and (B) SA-USPIO-PEG. Numbers 1–10 represent Fe concentrations ranging 
from 0.04-0.6 mM. 
 
 
Figure 5: R2 value curves of both NPs. 
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Figure 6: Cell viability of HL-7702 incubated with PEG-USPIO and SA-USPIO-PEG at various Fe concentrations. 
 
 
Figure 7: In vitro MR imaging of HepG2 and HL-7702 cells in different treatment groups. (A) T2 color maps, (B) T2WI MR 
images, and (C) normalized T2 signal intensities all demonstrate the most significant change in HepG2 cells in the pretargeting 
group. Abbreviations: Cont, control; NT, non-pretargeting; PT, pretargeting. 
approach. Both the T2 color maps and T2WI images 
showed the most significant signal intensity decrease in 
HepG2 cells in the pretargeting group (Figure 7A and 
7B). A quantitative analysis showed that the 
normalized signal intensity of HepG2 cells in the 
pretargeting group was lower than those of any other 
group (P<0.05), while the difference between the non-
pretargeting and pretargeting groups in HL-7702 cells 
was not statistically significant (Figure 7C). 
Prussian Blue Staining 
To evaluate the degree of NP uptake by tumor cells, 
Prussian blue staining was performed (Figure 8). In the 
pretargeting group, numerous blue granules were 
found in most HepG2 cells, in contrast to other groups 
with little to no blue granules. 
DISCUSSION 
In the present study, we demonstrated the potential 
of L5 peptide to serve as a specific ligand to guide 
magnetic NPs to GPC3-expressing HCC cells, as well 
as a way to intensify the signal, through a two-step 
pretargeting approach. 
1. High Specific Ligand for GPC3 
As an emerging molecular target for HCC, GPC3 
has attracted increasing attention in the past decade 
[11, 15, 25, 26]. Anti-GPC3 moAb and its F(ab’)2 
fragment have proven to be effective tools in enabling 
tumor-specific diagnosis through their ability to deliver 
imaging probes directly to the GPC3 receptor [12,16, 
26, 27]. Peptides have several advantages over moAb, 
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in that they are easy to synthesize and generally do not 
present with immunogenicity [18]. In a recent study by 
Lee’s group, L5 peptide was shown to have strong 
affinity and high specificity for GPC3 [23]. In agreement 
with Lee’s findings, direct immunofluorescence imaging 
and competitive binding assays in the present set of 
experiments demonstrated specific binding of L5 ligand 
to GPC3. Moreover, in vitro MRI showed a pronounced 
signal intensity decrease in the pretargeting HepG2 
group. The specificity of L5 peptide for GPC3 was 
further demonstrated by histologic examination. Of 
note, the signal intensities decreased approximately 
20% in the HL-7702 groups (both pretargeting and non-
pretargeting) and in the non-pretargeting HepG2 group 
compared to control, which might be caused by a non-
specific interaction between SA-USPIO-PEG particles 
and tumor or hepatic cells [26]. 
2. Modification of NPs 
Iron oxide-based contrast agents are widely used in 
the field of molecular MR imaging because of their 
favorable properties such as superparamagnetism and 
safety [28]. Given the large amount of Kupffer cells in 
the liver capturing and eliminating extraneous particles, 
it is necessary to modify the surface of NPs to optimize 
the delivery efficiency of USPIO to their cellular targets 
[7]. Incorporation of PEG helps overcome biologic 
delivering barriers, increase access to targeted 
molecules and improve the biocompatibility of NPs [8, 
29, 30]. In the present study, USPIO was coated with 
PEG and functionalized with SA; the resultant SA-
USPIO-PEG maintained a high T2 relaxivity, apart from 
showing low toxicity and a negative zeta potential. The 
negative surface charge allows deeper tissue 
penetration of SA-USPIO-PEG to the target by 
minimizing non-specific binding to surrounding tissues 
[31]. Also, the hydrodynamic size of nanoparticles is of 
importance, and is suggested to be controlled between 
10 nm and 100 nm [8]. In the present study, the mean 
hydrodynamic size of SA-USPIO-PEG was about 36 
nm. This would enable extravasation of the NP from 
leaky tumor vessels and accumulation in tumor cells 
via enhanced permeability and retention, while avoiding 
quick renal clearance [27, 32]. 
3. Biological Amplification for Molecular Imaging 
One drawback to this general approach is that 
peptides have lower avidity to targeted molecules than 
do antibodies, owing to their smaller molecular sizes 
[17]. This would have a negative influence on the 
sensitivity of molecular imaging. The strategy based on 
the avidin–biotin system, either a two-step or three-step 
 
Figure 8: Prussian blue staining of HepG2 and HL-7702 cells. Rich deposition of iron oxide particles (blue) is clear in the 
pretargeting group (PT) compared to non-pretargeting (NP) or control (Cont). 
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protocol, is a versatile method to amplify signal 
intensity, and thus was employed in the present study 
to handle the potentially lower amount of NP uptake by 
tumor cells [33, 34]. In this preliminary study, we chose 
the less complicated two-step pretargeting protocol. 
The biotinylated L5 peptide was administered first to 
bind GPC3 on tumor cells (pretargeting), and then SA-
NPs were administered to chase the biotinylated L5 
peptide. Our results indicated that the two-step protocol 
is feasible with biotinylated L5 peptide as a reporter 
molecule for HepG2 cells, and USPIO-PEG as the 
contrast agent. 
4. Limitations 
While they were designed to serve as preliminary 
inquiries, several limitations of the present experiments 
should be noted, and are being further investigated. 
First, we have shown proof of principle in terms of 
cellular and molecular biology; however, whether or not 
this strategy will sufficiently aid with visualization of a 
GPC3-expressing tumor in vivo needs to be 
investigated. Second, the comparison between an anti-
GPC3 monoclonal antibody and L5 peptide in terms of 
their efficacy to guide USPIO probes to tumor cells was 
not assessed. Further, since the pretargeting approach 
with avidin-biotin system is relatively complex, 
delivering magnetic NPs directly to HepG2 cells with a 
detectable L5 peptide, but without using the avidin-
biotin system, is more desirable. 
In summary, USPIO-based imaging probe with 
superparamagnetism and low cytotoxicity was 
synthesized, and the feasibility of the L5 peptide-
mediated two-step pretargeting approach to specifically 
identify GPC3-expressing HCC was validated using in 
vitro MRI. This detection method may be useful in the 
early detection and diagnosis of HCC and other 
targetable cancers. 
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